227 results about "Acute pain" patented technology

The invention discloses a newborn-painful-expression recognition method based on dual-channel-characteristic deep learning. The newborn-painful-expression recognition method includes the steps that firstly, newborn facial images are grayed, and a Local Binary Pattern (LBP) specific chromatogram is extracted; secondly, grayscale images of the parallelly-input newborn facial images and the characteristics of two channels of LBP characteristic images of the grayscale images are deeply learned with a dual-channel convolutional neural network; finally, the fusion characteristics of the two channels are subjected to expression classification through a classifier based on a softmax, and expressions are divided into the calmness expression, the crying expression, the mild pain expression and the acute pain expression. According to the newborn-painful-expression recognition method, the grayscale images and the characteristic information of the two channels of the LBP characteristic images of the grayscale images are combined, the expressions such as the calmness expression, the crying expression, the mild pain expression and the acute pain expression can be effectively recognized, the quite-good robustness of the illumination problem, the noise problem and the shielding problem of the newborn facial images is achieved, and a new method and way are provided for developing a newborn-painful-expression recognition system.

Disclosed are methods and systems and methods for patient-feedback control of non-invasive deep brain or superficial neuromodulation using sound impacting one or multiple points in a neural circuit to produce acute effects and, with application in multiple sessions, Long-Term Potentiation (LTP) or Long-Term Depression (LTD) to treat indications such as neurologic and psychiatric conditions. One or more of sonic transducer positioning, intensity, frequency, dynamic sweeps, phase/intensity relationships, and firing patterns are changed through feedback from the patient to optimize patient experience through up-regulation or down regulation. Examples are decreases in acute pain or tremor due to more effective impact on the neural targets.

The invention relates to a newborn painful expression recognition method based on a deep neural network. According to the method, a deep learning method based on a convolutional neural network (CNN) and a long and short term memory (LSTM) network is introduced and applied to newborn painful expression recognition work, and therefore expressions such as a slight pain and an acute pain caused when a newborn is in a silent or crying state and during pain inducing operation can be effectively recognized. The deep neural network is introduced to extract time domain features and spatial domain features of a video clip, therefore, the technical bottleneck in traditional manual design and extraction of explicit expression features is broken through, and the recognition rate and robustness under complicated conditions such as face sheltering, posture tilting and illumination changing are improved.

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

Disclosed are compounds of the formula (I) 1 wherein A, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and X.sub.1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chronic and acute pain.

The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I)

in which the groups Q¹-Q⁴, Ar, and R¹-R⁷ are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.

The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R¹ is a C1-6 alkyl group which may be substituted, R² is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R³ is a hydrogen atom or a C1-6 alkyl group, R⁴ is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.

The invention discloses a new traditional Chinese medicine combination and a preparation method for intestinal obstruction treatment; the raw materials of the traditional Chinese medicine combination include: agilawood, dalbergia wood, rhizome corydalis, sunburn frankincense, sunburn myrrh, rhizoma acori graminei, immature bitter orange, rhizome cyperi, cyperus rotundus, pangolins, szechwan chinaberry fruit, birthwor root, peach kernel, safflower, aspongopus, bunge cherry seed, ligusticum wallichii, salvia miltiorrhiza bunge, angelica, white paenoy root and the like. The traditional Chinese medicine combination can be prepared into any type of common oral preparation according to the conventional traditional Chinese medicine preparation method. The invention can significantly improve the symptoms of abdominal pain, abdominal distension, acute pain, intestinal obstruction, intestinal spasm and intestinal flatulence and the symptoms of vomit, body energy loss and difficult defecate caused by the former symptoms, has definite clinical curative effect, significant curative and quick effect. As the traditional Chinese medicine combination basically combines medicinal and edible medicine sources specified in the National Formulary, the traditional Chinese medicine combination has low cost and basically has no toxic and side effect.

In the present invention, Applicants demonstrate the effect of a biomembrane sealing agent on the development of chronic pain following tissue injury as well as acute pain in a model of acute inflammation. Applicants demonstrate the ability of this class of agents referred to as “biomembrane sealing agents” to reduce the severity of hyperalgesia and allodynia following mechanical insult to the nervous system as well as their ability to reduce acute pain in a model of acute inflammation. Applicant describes the use of injectable or depot formulations of biomembrane sealing agent(s) for prophylactic treatment such as they could be administered after the insult (i.e. post-injury or post-surgery) but before the onset of acute or chronic pain. Alternatively, biomembrane sealing agents could be used to reduce the severity of acute or chronic pain after onset.

Methods and systems for the transdermal delivery of sufentanil and its analogs are described, from patches having a unique pharmacodynamic profile that can be used to treat persistent pain over extended periods and acute pain episodes of limited duration.

Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains/sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed.

A method of treating acute pain in a patient in need thereof, the method comprising orally administering to the patient ambroxol or a pharmacologically acceptable salt thereof.

This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies.

New pharmaceutical compositions for oral use containing diclofenac preferably together with alkali metal bicarbonates in amounts of from about 20 to about 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher C_max of the active principle and shorter T_max together with a lower coefficient of variation.

Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given.